Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer

Philip J. Saylor, Umar Mahmood, Anchisa Kunawudhi, Matthew R. Smith, Edwin L. Palmer and M. Dror Michaelson
Journal of Nuclear Medicine November 2012, 53 (11) 1670-1675; DOI: https://doi.org/10.2967/jnumed.112.105007
Philip J. Saylor
1Division of Hematology–Oncology, Massachusetts General Hospital (MGH) Cancer Center, Boston, Massachusetts; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Umar Mahmood
2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anchisa Kunawudhi
2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew R. Smith
1Division of Hematology–Oncology, Massachusetts General Hospital (MGH) Cancer Center, Boston, Massachusetts; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwin L. Palmer
2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Dror Michaelson
1Division of Hematology–Oncology, Massachusetts General Hospital (MGH) Cancer Center, Boston, Massachusetts; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 53 no. 11 1670-1675
DOI 
https://doi.org/10.2967/jnumed.112.105007
PubMed 
22984218

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication February 29, 2012
  • Accepted for publication May 25, 2012
  • Published online November 1, 2012.

Article Versions

  • previous version (September 14, 2012 - 05:24).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2012 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Philip J. Saylor*,1,
  2. Umar Mahmood*,2,
  3. Anchisa Kunawudhi2,
  4. Matthew R. Smith1,
  5. Edwin L. Palmer2 and
  6. M. Dror Michaelson1
  1. 1Division of Hematology–Oncology, Massachusetts General Hospital (MGH) Cancer Center, Boston, Massachusetts; and
  2. 2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
  1. For correspondence or reprints contact: Umar Mahmood, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114.
View Full Text

Statistics from Altmetric.com

Cited By...

  • 16 Citations
  • 14 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
    Matthew Smith, Johann De Bono, Cora Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Ugo De Giorgi, Michael Krainer, Andries Bergman, Wolfgang Hoelzer, Ronald De Wit, Martin Bögemann, Fred Saad, Giorgio Cruciani, Antoine Thiery-Vuillemin, Susan Feyerabend, Kurt Miller, Nadine Houédé, Syed Hussain, Elaine Lam, Jonathan Polikoff, Arnulf Stenzl, Paul Mainwaring, David Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi
    Journal of Clinical Oncology 2016 34 25
  • Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
    M. Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, Lisa Sengeløv, Fred Saad, Nadine Houede, Peter Ostler, Arnulf Stenzl, Gedske Daugaard, Robert Jones, Fredrik Laestadius, Anders Ullèn, Amit Bahl, Daniel Castellano, Juergen Gschwend, Tristan Maurina, Edna Chow Maneval, Shaw-Ling Wang, Maria Jose Lechuga, Jolanda Paolini, Isan Chen
    Journal of Clinical Oncology 2014 32 2
  • A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases
    Richard J. Lee, Philip J. Saylor, M. Dror Michaelson, S. Michael Rothenberg, Malgorzata E. Smas, David T. Miyamoto, Carol A. Gurski, Wanling Xie, Shyamala Maheswaran, Daniel A. Haber, Jonathan G. Goldin, Matthew R. Smith
    Clinical Cancer Research 2013 19 11
  • Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
    Lina Yin, Qingzhong Hu, Rolf Hartmann
    International Journal of Molecular Sciences 2013 14 7
  • Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer
    Richard J. Lee, Matthew R. Smith
    The Cancer Journal 2013 19 1
  • The Multifaceted Role of Aldehyde Dehydrogenases in Prostate Cancer Stem Cells
    Jakob Püschel, Anna Dubrovska, Ielizaveta Gorodetska
    Cancers 2021 13 18
  • Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches
    Vittore Cereda, Vincenzo Formica, Gioia Massimiani, Livia Tosetto, Mario Roselli
    Expert Opinion on Investigational Drugs 2014 23 4
  • A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer
    Srikala S. Sridhar, Anthony M. Joshua, Richard Gregg, Christopher M. Booth, Nevin Murray, Jovana Golubovic, Lisa Wang, Pamela Harris, Kim N. Chi
    Clinical Genitourinary Cancer 2015 13 2
  • Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota
    Lin Chen, Yu-Xin Xu, Yuan-Shuo Wang, Ying-Ying Ren, Xue-Man Dong, Pu Wu, Tian Xie, Qi Zhang, Jian-Liang Zhou
    Molecular Cancer 2024 23 1
  • Molecular imaging of bone metastases using bone targeted tracers
    Sofia Vaz, Sharjeel Usmani, Gopinath Gnanasegaran, Tim Van den Wyngaert
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 63 2

Article usage

Article usage: September 2012 to April 2025

AbstractFullPdf
Sep 2012323026
Oct 2012299018
Nov 201214672386
Dec 20123971238
Jan 20133441527
Feb 201321699
Mar 201319869
Apr 2013127711
May 20131834745
Jun 2013931622
Jul 2013661411
Aug 2013842115
Sep 2013781724
Oct 2013821017
Nov 2013741611
Dec 201357614
Jan 2014521222
Feb 201449621
Mar 201488621
Apr 2014472615
May 2014784510
Jun 201456912
Jul 20144199
Aug 2014621411
Sep 201460412
Oct 201437710
Nov 20144463
Dec 20143755
Jan 201537219
Feb 201532126
Mar 201544127
Apr 2015341218
May 20153173
Jun 20152416
Jul 2015351613
Aug 201534108
Sep 20155157
Oct 20152828
Nov 20153584
Dec 201545158
Jan 201650137
Feb 201629715
Mar 2016551420
Apr 201637410
May 201619311
Jun 20163056
Jul 201636550
Aug 201625313
Sep 20161858
Oct 2016261416
Nov 201621128
Dec 20162453
Jan 201718109
Feb 20172164
Mar 2017151511
Apr 20171673
May 20172275
Jun 20171366
Jul 201717123
Aug 20171193
Sep 2017171410
Oct 20171595
Nov 201720710
Dec 201710206
Jan 20181139
Feb 201814719
Mar 201810714
Apr 2018221018
May 2018183614
Jun 201821129
Jul 20181889
Aug 20182086
Sep 201815911
Oct 201817712
Nov 201817815
Dec 2018131218
Jan 2019171513
Feb 201929162
Mar 201934258
Apr 201926174
May 2019733
Jun 2019733
Jul 20191493
Aug 20191078
Sep 2019846
Oct 20191018
Nov 2019503
Dec 2019949
Jan 202014124
Feb 2020446
Mar 20201138
Apr 2020513
May 2020713
Jun 20201228
Jul 2020702
Aug 2020418
Sep 2020545
Oct 202010510
Nov 20206411
Dec 2020542
Jan 20212325
Feb 202152913
Mar 20213326
Apr 20210394
May 20212298
Jun 20211416
Jul 202133411
Aug 202112513
Sep 202152913
Oct 202152318
Nov 202142018
Dec 20212365
Jan 20223319
Feb 20225277
Mar 20221255
Apr 20220265
May 202213513
Jun 202232213
Jul 20220221
Aug 20220206
Sep 202201721
Oct 20223217
Nov 20222206
Dec 20222204
Jan 202342310
Feb 2023394
Mar 20234149
Apr 20230196
May 2023177
Jun 20232101
Jul 202301111
Aug 2023587
Sep 20230132
Oct 202332011
Nov 20235147
Dec 20230115
Jan 20242168
Feb 202421310
Mar 20240722
Apr 202442317
May 202412013
Jun 20246288
Jul 20243469
Aug 202485516
Sep 20245126
Oct 202461910
Nov 2024389
Dec 20240151
Jan 202512010
Feb 202535111
Mar 202543511
Apr 2025103028
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 53 (11)
Journal of Nuclear Medicine
Vol. 53, Issue 11
November 1, 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer
Philip J. Saylor, Umar Mahmood, Anchisa Kunawudhi, Matthew R. Smith, Edwin L. Palmer, M. Dror Michaelson
Journal of Nuclear Medicine Nov 2012, 53 (11) 1670-1675; DOI: 10.2967/jnumed.112.105007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer
Philip J. Saylor, Umar Mahmood, Anchisa Kunawudhi, Matthew R. Smith, Edwin L. Palmer, M. Dror Michaelson
Journal of Nuclear Medicine Nov 2012, 53 (11) 1670-1675; DOI: 10.2967/jnumed.112.105007
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE STATEMENT
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
  • Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
  • A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

Keywords

  • bone scan
  • prostate cancer
  • tyrosine kinase inhibitor
  • Sunitinib
  • bone metastases
SNMMI

© 2025 SNMMI

Powered by HighWire